Integrum has signed an agreement with Bionics Group Ukraine LLC to enable a broadened distribution of OPRA® Implant System in Ukraine
Mölndal, Sweden, May 21, 2025 — Integrum AB (publ) (Nasdaq First North Growth Market: INTEG B) today announces that the company has entered a distribution agreement with Bionics Group Ukraine, LLC., a niche distributor-integrator of medical equipment for hospitals and private clinics in Ukraine. The agreement covers units that are used in the surgical implantation (S1 and S2 procedures) of the OPRA® Implant System.
Integrum has been present in Ukraine since May 2023, when the first prosthetic procedures using the OPRA® Implant System were performed by Dr. Rickard Brånemark. In December 2023, the company contributed to establishing a center of excellence for trauma care in Kyiv, with the aim to spearhead orthopedic treatments with the OPRA® Implant System in individuals who had suffered limb loss. Since then, approximately 80 patients have been treated with the implant system at the center.
The medical need remains high, as approximately 100,000 Ukrainians require treatment due to limb loss. To help address this issue and build a durable, long-term care infrastructure, the company targets critical bottlenecks by training medical personnel in the use of the OPRA® Implant System; thereby deepening the knowledge in endoprosthetic treatments and broadening the clinical experience of osseointegration technology.
The agreement with Bionics Group Ukraine, LLC, includes the full Integrum OPRA® Implant System suite, including AxorÔ II Prosthesis Connection Device and orthopedic devices used in humerus and digit implantations. This creates an opportunity for the company to formalize its distribution processes in Ukraine and take one step further in laying the foundation for a potential delivery chain scale-up.
“Our agreement with Bionics Group Ukraine is especially encouraging as Integrum has played an important role historically in supporting the establishment of state-of-the-art treatment facilities for patients who have suffered limb loss in Ukraine. The broadened distribution of our OPRA® Implant System strengthens the company’s presence further in the region, and it is an important step going forward and we see the long-term value in supporting medical specialists and regulatory agencies to build a robust and modernized healthcare infrastructure,” comments Martin Hillsten, CEO of Integrum.
For more information, please contact:
Martin Hillsten, CEO
Tel: +46 733 55 28 32
Email: martin.hillsten@integrum.se
Certified Adviser
The Company’s Certified Adviser is DNB Carnegie Investment Bank AB.
About integrum
Integrum AB is a publicly traded company (INTEG B: Nasdaq First North Growth Market) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA™ Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA™ Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/.